Articles

Antibody-drug conjugates (ADCs) are rapidly emerging as a transformative approach in cancer therapeutics, offering significant advancements over traditional treatments. The global ADC market is projected to reach $11.29 billion in 2023, with an estimated compound annual growth rate (CAGR) of 9.2% between 2024 and 2030, reflecting substantial economic and scientific interest in this field

Abstract Bioconjugate therapeutics comprise a fast-growing class of drugs with applications in various disease areas. In the past years, particularly antibody-drug conjugates (ADCs) have undergone...

Since Antibody-drug Conjugates (ADC) are already approved for the treatment of relapsed Hodgkin’s lymphoma, HER2-positive metastatic breast cancer and B cell lymphoma, among others, high expectations are placed on this class of bioconjugates. Indeed, more than 100 different ADCs have been studied for various applications by 2022, presumably with several more to follow.

Antibody-drug conjugates have achieved commercial success over the last 10 years with 15 therapies launched globally to date, including 11 with U.S. FDA approval, and two biosimilars. With their ability to direct highly potent cytotoxic payloads selectively to target cells, ADCs offer the prospect of more precise treatments and a reduction in off-target effects.

The European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for Byondis’ investigational next generation anti-HER2 antibody-drug conjugate (ADC) trastuzumab duocarmazine* in patients...

Over the last decades, outsourcing of pharmaceutical development and manufacturing, driven by a variety of factors, has resulted in the growth of Contract Development...